Our Approach
We envision a future where cancer therapy is built around the cells that actually cause harm. By profiling CTCs with single-cell precision, we identify the targets most relevant to metastatic disease and translate these into therapeutic development.
Our TzuPlus platform integrates the entire workflow under one roof. From CTC capture, through molecular characterisation, to bioinformatic target analysis. This allows us to move from patient samples to therapeutic insight.
TzuPlus Platform
1
Our Three Pillars
Our workflow is built upon three foundations that bridge the gap between diagnostic insight and therapeutics discovery
Standard blood draws capture only a handful of CTCs at best, and often too few to analyse reliably. Our TzuFetch technology has the ability to screen large blood volumes, recovering over 200 times more CTCs than conventional methods. This clinically validated approach provides thematerial needed for molecular analysis.
CTC enrichment & isolation
Once isolated, CTCs are profiled at single-cell level across three dimensions: genome-wide mutational profiling, full-length mRNA sequencing, and multiplex surface protein expression analysis. The result is a comprehensive molecular portrait of the cells driving metastasis, including theheterogeneity and co-expression of targets on single cells.
3
Bioinformatics & target identification
Our growing database of CTC profiles enables screening for target combinations that are highly expressed on metastasising cells and, co-expressed on CTCs. This data-driven approach guides the selection and development of therapeutic candidates.
